Form 4: United Therapeutics CEO Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 10 and May 13, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, the Chairperson and CEO of United Therapeutics, filed a Form 4 disclosing changes in beneficial ownership.
- On May 10 and May 13, 2024, Rothblatt exercised stock options and sold shares of United Therapeutics common stock.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- The plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
- On both May 10 and May 13, 3,600 stock options were exercised at a price of $129.49 per share.
- The sales on May 10 involved multiple transactions with weighted average prices ranging from $264.4381 to $269.1282.
- Similarly, the sales on May 13 were executed at weighted average prices ranging from $264.3926 to $268.885.
- Following these transactions, Rothblatt directly owns 255,869 derivative securities.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock transactions by a company executive under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard executive compensation practices and regulatory compliance.
Future Outlook
The reporting person's 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 723,869 stock options that expire December 31, 2024, or August 31, 2024.
Industry Context
Executive stock sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over time while avoiding accusations of trading on inside information. The market typically views these sales in the context of the executive's overall holdings and the company's performance.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across publicly traded companies.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
- The size and frequency of stock option exercises and sales can vary significantly based on company size, performance, and individual executive compensation agreements.
- The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations, similar to practices at companies like Pfizer and Johnson & Johnson.
Key Dates
| Date | Description |
|---|---|
| 2023-08-04 | Date the 10b5-1 trading plan was entered into by the reporting person. |
| 2024-05-10 | Date of stock option exercise and sale transactions. |
| 2024-05-13 | Date of stock option exercise and sale transactions. |
| 2024-05-14 | Date of Form 4 filing. |
| 2024-08-31 | End date of the 10b5-1 trading plan, if the tranche of stock options is not exhausted before this date. |
| 2024-12-31 | Expiration date of the tranche of 723,869 stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.